Dr. Camidge on AP26113 in Advanced Malignancies

D. Ross Camidge, MD, PhD
Published: Monday, Oct 07, 2013

D. Ross Camidge, MD, PhD, Director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, discusses the updated results of a first-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies. Data were presented at the 2013 European Cancer Conference in Amsterdam.

AP26113, a second-generation ALK inhibitor, has the broadest spectrum of activity of any of the second-generation inhibitors in terms of the known resistance mutations, Camidge says. 

AP26113 showed a 61% response rate in patients who are resistant to crizotinib, including one patient who was intolerant to crizotinib. Most interestingly, Camidge says, the study showed the agent had activity in brain metastases. The study showed that 8 out of 10 patients with active brain metastases were experiencing shrinkage following treatment with AP26113.

Camidge says the duration of benefit is not yet mature, but long-term central nervous system (CNS) responses were observed.

<<< View more from the 2013 European Cancer Congress

D. Ross Camidge, MD, PhD, Director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, discusses the updated results of a first-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies. Data were presented at the 2013 European Cancer Conference in Amsterdam.

AP26113, a second-generation ALK inhibitor, has the broadest spectrum of activity of any of the second-generation inhibitors in terms of the known resistance mutations, Camidge says. 

AP26113 showed a 61% response rate in patients who are resistant to crizotinib, including one patient who was intolerant to crizotinib. Most interestingly, Camidge says, the study showed the agent had activity in brain metastases. The study showed that 8 out of 10 patients with active brain metastases were experiencing shrinkage following treatment with AP26113.

Camidge says the duration of benefit is not yet mature, but long-term central nervous system (CNS) responses were observed.

<<< View more from the 2013 European Cancer Congress


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x